Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Metformin 1000 mg Clear all
Terminated Phase 1Phase 2 Interventional Results available

Metabolic Effects of Metformin Therapy in Obstructive Sleep Apnea

NCT04530747
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Metformin + PAP, Placebo oral capsule + PAP
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
35 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects

NCT01292993
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
400 mg LX4211, 1000 mg metformin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants

NCT06227832
View directory record Official record
Conditions
Healthy Adults
Interventions
KP-001, Metformin, Midazolam, Clarithromycin
Drug
Lead sponsor
Kaken Pharmaceutical
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

RISE Adult Medication Study

NCT01779362
View directory record Official record
Conditions
Prediabetes, Type 2 Diabetes
Interventions
Metformin, Liraglutide, Glargine, Placebo
Drug
Lead sponsor
RISE Study Group
Network
Eligibility
20 Years to 65 Years
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Sep 28, 2026, 6:13 PM EDT
Terminated Phase 2 Interventional Results available

Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.

NCT01578551
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Adenocarcinoma
Interventions
Paclitaxel, Carboplatin, Bevacizumab, Metformin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 28, 2026, 6:13 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

NCT03686657
View directory record Official record
Conditions
Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
Interventions
Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High
Drug
Lead sponsor
ARKAY Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fasting Conditions

NCT00778427
View directory record Official record
Conditions
Healthy
Interventions
metformin hydrochloride 1000 mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 22, 2008 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study

NCT01874080
View directory record Official record
Conditions
Diabetes
Interventions
Saxagliptin/Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Sep 28, 2026, 6:13 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

A Pragmatic Approach to Lowering the Risk of Diabetes Mellitus After A Diagnosis of Gestational Diabetes Mellitus

NCT04615351
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Metformin
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

NCT01975220
View directory record Official record
Conditions
Healthy
Interventions
Empagliflozin/Metformin XR FDC, 25 mg Empagliflozin/1000 mg Metformin XR, FDC, 1 tablet Empagliflozin/2 tablets Metformin XR, 1 tablet Empagliflozin/3 tablets Metformin XR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics

NCT03655301
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Copanlisib (Aliqopa, BAY80-6946), Metformin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 2 Interventional

Safety and Feasibility of Metformin for Sepsis Induced AKI

NCT05900284
View directory record Official record
Conditions
Sepsis, Septic Shock, Acute Kidney Injury, Metformin
Interventions
Metformin low dose, Metformin high dose, Placebo
Drug
Lead sponsor
Hernando Gomez
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 28, 2026, 6:13 PM EDT
Terminated Phase 1 Interventional Results available

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

NCT01525225
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 2 Interventional Results available

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

NCT01068860
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Canakinumab 150 mg, Placebo to Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2011 · Synced Sep 28, 2026, 6:13 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

NCT02969798
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Interventions
Dapagliflozin, Saxagliptin, Pioglitazone, Metformin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

NCT01555164
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
60
States / cities
Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851212
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Sep 28, 2026, 6:13 PM EDT
Terminated Phase 1 Interventional

An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin

NCT01816659
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Metformin ER
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 3 Interventional Results available

Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes

NCT00789191
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, sitagliptin, metformin, sulphonylurea
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Vestavia Hills, Alabama • Orange, California • Santa Monica, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

NCT02526524
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Met DR, Met IR, Placebo
Drug
Lead sponsor
Elcelyx Therapeutics, Inc.
Industry
Eligibility
25 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
134
States / cities
Anniston, Alabama • Birmingham, Alabama • Tuscumbia, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 2 Interventional Results available

Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance

NCT00443755
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome
Interventions
metformin, pioglitazone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 28, 2026, 6:13 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Cardio Risk of Acute Schizophrenia Olanzapine Duke

NCT00672464
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine, Metformin, Simvastatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Butner, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL

NCT01750567
View directory record Official record
Conditions
Relapsed Chronic Lymphocytic Leukemia
Interventions
Metformin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 28, 2026, 6:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)

NCT00897390
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, Metformin IR (glucophage), Saxagliptin + Metformin IR (FDC)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 28, 2026, 6:13 PM EDT